StockVS

Rafael Holdings, Inc. (RFL) Stock Analysis

Real Estate

Rafael Holdings, Inc.

$1.32

$-0.02 (-1.49%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, as well as medical devices, with operations spanning the United States and Israel. The company operates within the Real Estate sector and specifically within the Real Estate Services industry, distinguishing its business model from traditional property management by focusing on service-based real estate activities alongside its healthcare investments. The company's current scale is defined by a market capitalization of $65.02M and an annual revenue of $1.16M, supported by an employee base of 21 individuals. These valuation figures indicate a small-cap entity where revenue generation is limited relative to the market cap, suggesting a capital structure heavily reliant on retained earnings or external financing rather than organic revenue scaling. The disparity between the $65.02M market cap and the $1.16M revenue highlights a valuation model that prices the stock based on asset holdings or future potential rather than current operational cash flow.

Financial Health

Rafael Holdings, Inc. reported a trailing twelve-month revenue of $1.16M, yet the net income for the same period was a loss of $-33,106,000, revealing a significant divergence where operating expenses and non-operating costs far exceeded total revenue generation. The company's EBITDA stands at $-34,455,000, indicating that even before interest, taxes, depreciation, and amortization, the core business operations are generating a substantial negative cash flow. Despite these significant losses, the company maintains a free cash flow of $184,250, which suggests a degree of financial flexibility potentially derived from non-operating activities or specific asset disposals rather than primary business operations. The gross margin is exceptionally high at 93.1%, while the operating margin is severely negative at -3154.0%, and the profit margin is recorded at 0.0%, collectively indicating a cost structure where fixed costs and interest expenses are the primary drivers of the bottom-line deficit. On the balance sheet, the company holds $37.78M in cash against $660,000 in debt, resulting in a debt-to-equity ratio of 0.79, which portrays a conservative stance regarding leverage despite the operating losses. The current ratio is 3.44, indicating a robust position in short-term liquidity where current assets significantly outweigh current liabilities. Return on Equity is -41.4% and Return on Assets is -23.8%, metrics that reveal management is currently utilizing the company's capital base to generate value destruction rather than value creation.

Valuation Assessment

Both the trailing P/E ratio and the forward P/E ratio are listed as N/A due to the negative earnings, a status that implies the market cannot value the stock based on traditional multiple expansion of current profits. The price-to-book ratio is 0.82, indicating that the market values the company at a discount to its net asset value, suggesting a perception of undervaluation or concerns regarding asset quality. The price-to-sales ratio is 55.90, while the EV/EBITDA is -0.93; these alternative metrics suggest the market is pricing the stock based on asset holdings or specific growth potential rather than sales efficiency. The 52-week high is $3.19 and the 52-week low is $1.12, placing the current trading range within a volatile band where the stock fluctuates significantly over the annual period. The beta value is 0.54, which indicates that the stock's price volatility is less than that of the broader market, offering a lower correlation to general market swings compared to high-beta equities.

Growth & Income

Revenue growth year-over-year is 174.0%, while earnings growth is N/A due to the reported losses, implying that revenue expansion is not yet translating into profitability and that earnings are growing at a rate that is mathematically undefined by positive numbers. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources into its business operations or debt reduction rather than distributing income to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion in the absence of earnings, coupled with a complete retention of earnings rather than dividend distribution. This profile suggests a company in a high-risk, high-revenue-growth phase where shareholder returns are currently generated through potential capital appreciation rather than dividend income.

Peer Comparison

Rafael Holdings, Inc. (RFL) operates in the Real Estate Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rafael Holdings, Inc. RFL $69.70M N/A
CBRE Group, Inc. CBRE $38.00B 29.6
KE Holdings Inc. BEKE $18.40B 37.5
Jones Lang LaSalle Incorporated JLL $13.43B 15.6

The Real Estate Services industry average P/E ratio is 84.5x. Rafael Holdings, Inc. trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Visit website →

Key Statistics

Market Cap
$69.70M
P/E Ratio
N/A
52-Week High
$3.19
52-Week Low
$1.12
Avg Volume
79.23K
Beta
0.49

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NYSE
Country
United States
Employees
21